Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal metastases from colorectal cancer in the Czech Republic in 2018

Czech version

Authors: L. Němec ¹; J. Novák ²; J. Mužík ^3,4; D. Krejčí ^3,4; J. Tomášek ⁵; R. Šefr ¹; P. Bartoška ⁶; F. Antoš ⁶; P. Dytrych ⁷; D. Hoskovec ⁷; M. Levý ⁸; J. Šimša ⁸; Dušan Klos ⁹; Č. Neoral ⁹
Authors‘ workplace: Klinika operační onkologie LF MU a MOÚ Brno ¹; Úsek národního onkologického registru, MOÚ Brno ²; Institut bio statistiky a analýz, LF MU Brno ³; Ústav zdravotnických informací a statistiky ČR, Praha ⁴; Klinika komplexní onkologické péče LF MU a MOÚ Brno ⁵; Chirurgická klinika 1. LF UK, IPVZ a Nemocnice Na Bulovce, Praha ⁶; I. chirurgická klinika 1. LF UK a VFN v Praze ⁷; Chirurgická klinika 1. LF UK a Thomayerovy nemocnice, Praha ⁸; I. chirurgická klinika LF UP a FN Olomouc ⁹
Published in: Klin Onkol 2021; 34(4): 278-282
Category: Review
doi: https://doi.org/10.48095/ccko2021278

Overview

Background: For highly selected patients with peritoneal metastases (PM) from colorectal cancer (CRC), an aggressive surgical approach with intraperitoneal chemotherapy may be beneficial. This management may prolong overall survival, which is well documented by the results of a number of clinical trials. In the Czech Republic, five specialized centers of surgical oncology are able to perform cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC). All of these centers provided accurate information on the number of CRS procedures in 2018 in the PM CRC indication. The estimation of the prevalence of peritoneal metastases from CRC is based on data from the Czech National Cancer Registry. Purpose: To determine the number of cytoreductive procedures performed in patients with peritoneal metastases from CRC in the Czech Republic in 2018, and to compare it with the number of patients who could hypothetically benefit from this procedure according to statistical data. Results: Twenty-five CRS/HIPEC procedures were performed on patients with peritoneal metastases from CRC in 2018 in the Czech Republic. However, based on the prevalence of peritoneal metastases from CRC in the Czech Republic, cytoreduction with intraperitoneal chemotherapy (CRS/HIPEC) could probably bring benefit to a minimum of 150 patients a year in the Czech Republic. Conclusion: In the Czech Republic in 2018, the cytoreduction and HIPEC procedures for peritoneal metastases from CRC were performed in significantly fewer cases than would correspond to the estimated number of potentially curable patients.To increase the awareness of this issue and improve the number of potentially curative cytoreductive procedures, there will be necessary better awareness and closer cooperation among specialized centers, general surgeons, and clinical oncologists.

Keywords:

cytoreductive surgery – intraperitoneal chemotherapy – peritoneal metastases – colorectal cancer

Sources

1. Krška Z, Hoskovec D, Petruželka L et al. Chirurgická onkologie. Praha: Grada Publishing 2014.

2. Simkens GA, Rovers KP, Nienhuijs SW et al. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res 2017; 9: 259–266. doi: 10.2147/CMAR.S119569.

3. Elias D, Honoré C, Dumont F et al. Results of systematic second-look surgery plus hipec in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2011; 254 (2): 289–293. doi: 10.1097/SLA.0b013e31822638f6.

4. Rosen SA, Buell JF, Yohida A et al. Initial presentation with stage IV colorectal cancer. Arch Surg 2000; 135 (5): 503–505. doi: 10.1001/ARCHSURG.135.5.530.

5. Simkens GA, Razenberg LG, Lemmens VE et al. H. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases. Eur J Surg Oncol 2016; 42 (6): 794–800. doi: 10.1016/j.ejso.2016.03.014.

6. Lemmens VE, Klaver YL, Verwaal VJ et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011; 128 (11): 2717–2725. doi: 10.1002/ijc.25596.

7. Segelman J, Granath F, Holm T et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012; 99 (5): 699–705. doi: 10.1002/bjs.8679.

8. Kerscher AG, Chua TC, Gasser M et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer 2013; 108 (7): 1432–1439. doi: 10.1038/bjc.2013.82.

9. Segelman J, Akre O, Gustafsson UO et al. A. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. Colorectal Dis 2014; 16 (5): 359–367. doi: 10.1111/codi.12552.

10. Koppe MJ, Boerman OC, Oyen WJ et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243 (2): 212–222. doi: 10.1097/01.sla.0000197702.46394.16.

11. Kok NF, de Hingh IH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin. BJS 2017; 104 (4): 313–315. doi: 10.1002/bjs.10422.

12. Koh JL, Yan TD, Glenn D et al. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 2009; 16 (2): 327–333. doi: 10.1245/s10434-008-0234-2.

13. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82: 359–374. doi: 10.1007/978-1-4613-1247-5_23.

14. Bartoška P, Antoš F, Němec L et al. Maligní nádory peritonea – úvod do problematiky. Klin Onkol 2019; 32 (5): 324–328. doi: 10.14735/amko2019324.

15. Němec L, Tomášek J, Šefr R. Léčba a profylaxe peritoneálních metastáz kolorektálního karcinomu. Klin Onkol 2019; 32 (5): 338–344. doi: 10.14735/amko2019338.

16. Antoš F. Peritoneální nádory, Klin Onkol 2019; 32 (5): 321.

17. Antoš F. Dytrych P. Vítek P. et al. Maligní ascites – možnost ovlivnění tvorby pomocí hypertermické peroperační chemoterapie (HIPEC). Rozhl Chir 2010; 89 (4): 237–241.

18. Razenberg LG, van Gestel YR, Creemers GJ et al. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands. Eur J Surg Oncol 2015; 41 (4): 466–471. doi: 10.1016/j.ejso.2015.01.018.

19. Bhatt A. Management of peritoneal metastases- cytoreductive surgery, HIPEC and beyond. Singapore: Springer 2018.

20. Franko J, Shi Q, Meyers JP et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 2016; 17 (12): 1709–1719. doi: 10.1016/S1470-2045 (16) 30500-9.

21. Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27 (5): 681–685. doi: 10.1200/JCO.2008.19.7160.

22. Elias D, Gilly F, Boutitie F et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28 (1): 63–68. doi: 10.1200/JCO.2009.23.9 285.

23. Esquivel J, Lowy AM, Markman M et al. The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution evaluation of the peritoneal surface disease severity score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol 2014; 21 (13): 4195–4201. doi: 10.1245/s10434-014-3798-z.

24. Glehen O, Kwiatkowski F, Sugarbaker PH et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22 (16): 3284–3292. doi: 10.1200/JCO.2004.10.012

25. Kuijpers AM, Mirck B, Aalbers AG et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 2013; 20 (13): 4224–4230. doi: 10.1245/s10434-013-3145-9.

26. Esquivel J, Piso P, Verwaal V et al. American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol 2014; 110 (7): 777–778. doi: 10.1002/jso.23722.

27. Chua TC, Esquivel J, Pelz JO et al. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol 2013; 107 (6): 566–573. doi: 10.1002/jso.23189.

28. El-Nakeep S, Rashad N, Oweira H et al. Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review. Expert Rev Gastroenterol Hepatol 2017; 11 (3): 249–258. doi: 10.1080/17474124.2017.1284586.

29. Kwakman R, Schrama AM, van Olmen JP et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg 2016; 263 (6): 1102–1111. doi: 10.1097/SLA.0000000000001593.

30. Quenet F, Elias D, Roca L et al. A UNICANCER phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. [online]. Available from: https: //ascopubs.org/doi/10.1200/JCO.2018.36.18_suppl.LBA3503.

31. März L, Piso P: Treatment of peritoneal metastases from colorectal cancer. Gastroenterology Report 2015; 3 (4): 298–302. doi: 10.1093/gastro/gov044.

32. Elias D, Mariani A, Cloutier AS et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 2014; 40 (11): 1467–1473. doi: 10.1016/j.ejso.2014.06.006.

33. Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: Progress toward a new standard of care. Cancer Treat Rev 2016; 48: 42–49. doi: 10.1016/j.ctrv.2016.06.007.

34. Ha SH, Park SY, Park JS et al. Short-term outcomes after laparoscopic cytoreductive surgery in patients with limited peritoneal metastases from colorectal cancer. Surgery 2019; 165 (4): 775–781. doi: 10.1016/j.surg.2018.09. 017.

35. Baratti D, Kusamura S et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. Crit Rev Oncol Hematol 2016; 100: 209–222. doi: 10.1016/j.critrevonc.2016.01.017.